Skip to main content
. 2016 May 5;7(23):34785–34799. doi: 10.18632/oncotarget.9185

Figure 3. LY2603618 treatment results in DNA double strand breaks.

Figure 3

(A) U937 cells were treated with LY for 24 h, then fixed with ethanol and stained with PI for cell cycle analysis. (B) U937 cells were treated with LY for 24 h. Whole cell lysates were subjected to Western blotting. The fold changes for the γH2AX, p-CDC25C, and p-CDK1 densitometry measurements, normalized to β-actin and then compared to no drug treatment control, are indicated. (C) U937 cells were treated with LY and Roscovitine (ROSC), alone or in combination, for 16 h and then subjected to alkaline comet assay analysis. Representative images are shown. (D) Comet assay results are graphed as median percent DNA in the tail from 4 replicate gels ± s.e.m. **indicates p < 0.005 and ***indicates p < 0.0005. (E) Primary AML patient sample AML#111 was treated with LY and Roscovitine (ROSC), alone or in combination, for 16 h and then subjected to alkaline comet assay analysis. Representative images are shown. (F) Comet assay results are graphed as median percent DNA in the tail from 4 replicate gels ± s.e.m. **indicates p < 0.005. (G–J) CTS and U937 cells were treated with LY and ROSC, alone or in combination for 24 h. The cells were subjected to Annexin V/PI staining and flow cytometry analysis (G and I). ***indicates p < 0.0005. Whole cell lysates were subjected to Western blotting (H&J).